SUTRO BIOPHARMA, INC. — Director's Dealing 2021

Feb 1, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SUTRO BIOPHARMA, INC. (STRO)
CIK: 0001382101
Period of Report: 2021-01-29

Reporting Person: Hallam Trevor (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-29	Common Stock	M	5250	$0.00	Acquired	61367	Direct
2021-01-29	Common Stock	F	2080	$22.15	Disposed	59287	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-29	Restricted Stock Unit (RSU)	$	M	5250	Disposed	2024-01-29	Common Stock (5250)	Direct

Footnotes

F1: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person.

F2: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.

F3: The RSUs vest as to 1/4th of the total shares annually beginning on January 29, 2021, subject to continued service through each vesting date.